Univariate analysis of PM PET and MFC negativity for PFS and OS
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS | |||
| All patients | |||
| PM PET negativity | 0.48 | 0.25-0.90 | .019 |
| PM MFC negativity | 0.38 | 0.25-0.57 | <.0001 |
| Patients treated with daratumumab | |||
| PM PET negativity | 0.35 | 0.17-0.71 | .0023 |
| PM MFC negativity | 0.40 | 0.23-0.68 | .0005 |
| OS | |||
| All patients | |||
| PM PET negativity | 0.37 | 0.12-1.07 | .056 |
| PM MFC negativity | 0.79 | 0.32-1.97 | .61 |
| Patients treated with daratumumab | |||
| PM PET negativity | 0.32 | 0.11-0.96 | .033 |
| PM MFC negativity | 0.60 | 0.22-1.62 | .31 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS | |||
| All patients | |||
| PM PET negativity | 0.48 | 0.25-0.90 | .019 |
| PM MFC negativity | 0.38 | 0.25-0.57 | <.0001 |
| Patients treated with daratumumab | |||
| PM PET negativity | 0.35 | 0.17-0.71 | .0023 |
| PM MFC negativity | 0.40 | 0.23-0.68 | .0005 |
| OS | |||
| All patients | |||
| PM PET negativity | 0.37 | 0.12-1.07 | .056 |
| PM MFC negativity | 0.79 | 0.32-1.97 | .61 |
| Patients treated with daratumumab | |||
| PM PET negativity | 0.32 | 0.11-0.96 | .033 |
| PM MFC negativity | 0.60 | 0.22-1.62 | .31 |